Article (Scientific journals)
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).
Parenti, Giancarlo; Fecarotta, Simona; Alagia, Marianna et al.
2024In Orphanet Journal of Rare Diseases, 19 (1), p. 408
Peer Reviewed verified by ORBi
 

Files


Full Text
13023_2024_Article_3373.pdf
Publisher postprint (1.57 MB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Acid alpha-glucosidase deficiency; Acid maltase deficiency; Glycogen storage disease (GSD) type II; Lysosomal storage disease; Pompe disease; Humans; Critical Pathways; Europe; Glycogen Storage Disease Type II/metabolism; Glycogen Storage Disease Type II/diagnosis; Glycogen Storage Disease Type II; Genetics (clinical); Pharmacology (medical)
Abstract :
[en] Clinical pathway recommendations (CPR) are based on existing guidelines and deliver a short overview on how to deal with a specific diagnosis, resulting therapy and follow-up. In this paper we propose a methodology for developing CPRs for Pompe disease, a metabolic myopathy caused by deficiency of lysosomal acid alpha-glucosidase. The CPR document was developed within the activities of the MetabERN, a non-profit European Reference Network for Metabolic Diseases established by the European Union. A working group was selected among members of the MetabERN lysosomal storage disease subnetwork, with specific expertise in the care of Pompe disease, and patient support group representatives. The working strategy was based on a systematic literature search to develop a database, followed by quality assessment of the studies selected from the literature, and by the development of the CPR document according to a matrix provided by MetabERN. Quality assessment of the literature and collection of citations was conducted according to the AGREE II criteria and Grading of Recommendations, Assessment, Development and Evaluation methodology. General aspects were addressed in the document, including pathophysiology, genetics, frequency, classification, manifestations and clinical approach, laboratory diagnosis and multidisciplinary evaluation, therapy and supportive measures, follow-up, monitoring, and pregnancy. The CPR document that was developed was intended to be a concise and easy-to-use tool for standardization of care for patients among the healthcare providers that are members of the network or are involved in the care for Pompe disease patients.
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Parenti, Giancarlo ;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands. parenti@unina.it ; Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, Naples, Italy. parenti@unina.it ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy. parenti@unina.it ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy. parenti@unina.it
Fecarotta, Simona;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Alagia, Marianna;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Attaianese, Federica;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Verde, Alessandra;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Tarallo, Antonietta;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, Naples, Italy ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Gragnaniello, Vincenza;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Ziagaki, Athanasia;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Endocrinology and Metabolism, Center of Excellence for Rare Metabolic Diseases in Adults, Charite-Universitätsmedizin Berlin, Berlin, Germany
Guimaraes, Maria Jose';  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Pneumology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal
Aguiar, Patricio;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Clinica Universitaria de Medicina I, Universidade de Lisboa, Lisbon, Portugal
Hahn, Andreas;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Child Neurology, Justus-Liebig University, Giessen, Germany
Azevedo, Olga;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Cardiology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal ; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal ; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal
Donati, Maria Alice;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Metabolic and Neuromuscular Unit, Meyer Children Hospital-University of Florence, Florence, Italy
Kiec-Wilk, Beata;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Unit of Rare Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland ; The John Paul II Specjalist Hospital in Kraków, Kraków, Poland
Scarpa, Maurizio;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Centro Coordinamento Regionale Malattie Rare, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy
van der Beek, Nadine A M E;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Center for Lysosomal and Metabolic Diseases, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands
Del Toro Riera, Mireja;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Metabolic Unit, Department of Pediatric Neurology, Hospital Universitario Vall d'Hebron Barcelona, Barcelona, Spain
Germain, Dominique P;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Division of Medical Genetics, University of Versailles, Montigny, France
Huidekoper, Hidde;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
van den Hout, Johanna M P;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
van der Ploeg, Ans T;  MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands. a.vanderploeg@erasmusmc.nl ; Center for Lysosomal and Metabolic Diseases, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. a.vanderploeg@erasmusmc.nl
and the MetabERN Subnetwork for Lysosomal Disorders
Debray, François-Guillaume ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Maladies métaboliques d'origine génétique
More authors (13 more) Less
Language :
English
Title :
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).
Publication date :
01 November 2024
Journal title :
Orphanet Journal of Rare Diseases
eISSN :
1750-1172
Publisher :
BioMed Central Ltd, England
Volume :
19
Issue :
1
Pages :
408
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
We gratefully acknowledge members of MetabERN Subnetwork for Lysosomal Disorders who reviewed the manuscript. MetabERN Subnetwork for Lysosomal Disorders: Ivo Baric1, Spyros Batzios2, Nadia Belmatoug3, Andrea Bordugo4, Annet M. Bosch5, Anais Brassier6, Alberto Burlina7, David Cassiman8, Brigitte Chabrol9, Efstathia Chronopoulou10, Maria Luz Couce-Pico11, Niklas Darin12, Anibh M. Das13, Francois G. Debray14, Patrick Deegan15, Luisa M. de Abreu Freire Diogo Matos16, Javier De Las Heras Montero17, Maja Di Rocco18, Dries Dobbelaere19, Francois Eyskens20, Ana Ferreira21, Ana M. Gaspar22, Serena Gasperini23, Antonio Gonz\u00E1lez-Meneses L\u00F3pez24, Salvatore Grosso25, Nathalie Guffon-Fouilhoux26, Julia Hennermann27, Tarekegn G. Hiwot28, Simon Jones29, Sandra Kingma20, Veroniki Komninaka30, Elena Mart\u00EDn-Hern\u00E1ndez31, Esmeralda Martins32, Diana Miclea33, Gy\u00F6rgy Pfliegler34, Esmeralda Rodrigues35, Dariusz Rokicki36, Dominique Roland37, Frank Rutsch38, Alessandro Salviati39, Ivailo Tournev40, Kurt Ullrich41, Peter M. van Hasselt42, Suresh Vijay43, Natalie Weinhold44, Peter Witters45, Jiri Zeman46. 1University Hospital Center Zagreb, Croatia; 2Great Ormond Street Hospital NHS Foundaton Trust, London, United Kingdom; 3H\u00F4pital Beaujon de Paris, France; 4Azienda Ospedaliera Universitaria Integrata di Verona, Italy; 5Academic Medical Center of Amsterdam, Netherlands; 6 Hospital Necker des Enfants Malades, APHP, University Paris Descartes, Paris, France.; 7 University Hospital of Padova, Italy; 8 University of KU Leuven, Belgium; 9University hospital of Marseille, France; 10Department of Inherited Metabolic Disease, Division of Women's and Children's Services, University Hospitals Bristol NHS Foundation Trust, Bristol, UK; 11University Clinical Hospital of Santiago de Compostela, Spain; 12Sahlgrenska Hospital, Gothenburg, Sweden; 13Hannover Medical School, Germany; 14Centre Hospitalier Universitaire de Li\u00E8ge, Belgium; 15Cambridge University Hospitals NHS Foundation Trust (CUH), United Kingdom; 16Centro Hospitalar e Universit\u00E1rio de Coimbra, EPE, Portugal; 17Hospital Universitario Cruces, Spain; 18G. Gaslini Institute (IRCCS), Genova, Italy; 19University Hospital of Lille, France; 20University Hospital of Antwerp, Center of Inherited Metabolic Diseases, Belgium; 21Centro Hospitalar Lisboa Central, Portugal; 22Centro Hospitalar Lisboa Norte, EPE, Portugal; 23San Gerardo Hospital, Monza, Italy; 24Hospital Virgen del Rocio, Sevilla, Spain; 25Azienda Ospedaliera Universitaria Senese, Italy; 26University Hospital of Lyon, France; 27University Medical Center Mainz, Germany; 28University Hospital of Birmingham NHS Foundation Trust, United Kingdom; 29Central Manchester University Hospitals NHS Trust, United Kingdom; 30Laiko General Hospital of Athene, Greece; 31Hospital Universitario 12 de Octubre, Madrid, Spain; 32Centro Hospitalar do Porto, EPE (CHP), Portugal; 33Clinical Emergency Hospital for children, Cluj-Napoca, Romania; 34University of Debrecen, Hungary; 35Centro Hospitalar do Sao Joao, EPE, Portugal; 36The Children\u2019s Memorial Health Institute of Warsaw, Poland; 37Belgium Center Inter Institutional for Metabolic Diseases (CIMM); 38University Hospital of Muenster, Germany; 39Department of Biotechnology, University of Verona, Italy; 40University hospital \"Alexandrovska\", Sofia, Bulgaria; 41University Medical Center Hamburg-Eppendorf, Germany; 42University Medical Center Utrecht (UMCU), Netherlands; 43Birmingham Children\u2019s Hospital NHS Foundation Trust, United Kingdom; 44Charit\u00E9-Universit\u00E4tsmedizin, Berlin, Germany; 45Universitair Ziekenhuis of Leuven, Belgium; 46General University Hospital in Prague, Czech Republic.GP has received funding for research and clinical trials and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, Orchard, Synageva/Alexion, BioMarin, Denali, Takeda. SF has received honoraria, consulting fees, speaker fees and travel reimbursement. From Sanofi, Amicus, Alexion, Chiesi. MJG has received educational and research grants from Sanofi Genzyme. PRTA received grant/research support from Takeda, and speaker/travel. honoraria from Takeda, Sanofi-Genzyme, BioMarin, Ultragenyx, Alexion, Amicus Therapeutics, and Chiesi.. OA has received educational/research grants from Shire Human Genetic Therapies/Takeda and travel/accommodation support for conferences from Shire Human Genetic. Therapies/Takeda, Amicus and Sanofi Genzyme. MAD received travel grants for scientific meetings and honoraria for speaking. engagements from Shire International, Sanofi Genzyme and BioMarin. MS has received honoraria, research and travel grants from Alexion, BioMarin. Pharmaceutical Inc., Chiesi, Sanofi Genzyme, Shire, Ultragenix and Sangamo. NAMEvdeB has received consulting fees and travel reimbursement from Sanofi andAmicus Therapeutics and received funding for research, clinical trials, and advisory fees from Sanofi. MDTR has received consulting fees and speaker honoraria, travel expenses, and congress fees from Biomarin, Sanofi Genzyme, Takeda,and has participated in trials sponsored by Orphazyme, Takeda, Vtesse-Sucampo Mallinckrodt). DPG has received consulting honoraria from Chiesi, Idorsia Pharmaceuticals, Sanofi and Takeda, and speaker honoraria and travel support from Sanofi and Takeda. HH reports advisory board fees, speaker fee, and a clinical trial agreement from BioMarin. JMPvdH received funding for research, clinical trials, and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, BioMarin, Sarepta, Denali, Takeda and Chiesi. ATvdP has received grant for clinical trials conduction from Amicus Therapeutics andSanofi-Genzyme. MA, FA, AV, AT, VG, AZ, AH, BKW have no conflicts of interest to declare.
Available on ORBi :
since 17 February 2026

Statistics


Number of views
15 (0 by ULiège)
Number of downloads
3 (0 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
11
OpenCitations
 
10
OpenAlex citations
 
17

Bibliography


Similar publications



Contact ORBi